VIDEO: Small study assesses intermittent ipilimumab, nivolumab metastatic RCC
Click Here to Manage Email Alerts
SAN FRANCISCO — Moshe Ornstein, MD, spoke with Healio about a trial of intermittent therapy in patients with metastatic renal cell carcinoma presented at the annual ASCO Genitourinary Cancers Symposium.
The phase study was conducted among patients with metastatic RCC who were treated with frontline ipilimumab (Yervoy, Bristol Myers Squibb) and nivolumab (Opdivo, Bristol Myers Squibb), according to the abstract. The combination of ipilimumab and nivolumab is currently approved for the treatment of intermediate- and poor-risk disease.
“However, there are two big questions that are unanswered, and we were hoping to answer some of those with this study,” Ornstein, an author on the study and genitourinary medical oncologist at Cleveland Clinic Taussig Cancer Institute, said. “Question number one is, how long do patients need to be on therapy? Is there a role to stop therapy early? Can they be on therapy for a shorter amount of time, instead of indefinite therapy? nd second, for patients who’ve already received ipilimumab and nivolumab for metastatic RCC, is there a role at the time that their cancer progresses to give them reinduction ipilimumab and nivolumab?”
Reference:
- George L, et al. Abstract 672. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts